Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant nivolumab with PD-L1 PET imaging in resectable locally advanced oral cancer
NL-OMON50077Active, not recruiting
- Sponsor
- Vrije University Medical Center
- Start
- Sep 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of nivolumab in mouth cancer and head and neck squamous cell carcinoma (HNSCC), sponsored by Vrije University Medical Center. Primary endpoints: Primary endpoint 1 and Primary endpoint 2. Started Sep 2019; status: active, not recruiting.
02
Drugs
03
Conditions
mouth cancerhead and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NL-OMON50077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50077.